Navigation Links
Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
Date:3/31/2009

>

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America, Europe, Japan and Taiwan. Clevudine is already approved for HBV in South Korea and the Philippines. It is marketed in Korea by Bukwang Pharmaceuticals under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, has completed a 4-week clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche, and is initiating a Phase 2b trial. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involvin
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Reports Fiscal Year End 2008 Financial Results
2. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
3. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
4. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
5. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
6. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
7. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
8. Pharmasset Receives Notice of Allowance
9. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
10. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
11. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)...   MultiVir Inc. ("MultiVir"), a clinical-stage gene ... for the treatment of multiple oncological indications, today announced ... Form S-1 with the U.S. Securities and Exchange Commission ... shares of its common stock. The number of shares ... proposed offering have not yet been determined. MultiVir has ...
(Date:3/30/2015)... , March 30, 2015   CSL ... Agency (EMA) has started the Centralized Procedure for ... its long-acting fusion protein linking recombinant coagulation factor ... approval, rIX-FP will provide hemophilia B patients in ... European Economic Area (EEA) countries, with a long-acting ...
(Date:3/30/2015)... SAN DIEGO , March 30, 2015 ... the appointment of George K. Ng to ... Officer.  In this capacity, Mr. Ng will be responsible ... Mr. Ng joins the Company from BioDelivery Sciences ... General Counsel and a member of senior management that ...
Breaking Medicine Technology:MultiVir Files Registration Statement for Proposed Initial Public Offering 2European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients 2European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients 3European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients 4Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer 2Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer 3
... , NEW YORK, Oct. 13 Reportlinker.com ... is available in its catalogue. , ... Outlook to 2010: Marketing and Sales Strategies ... , http://www.reportlinker.com/p0154807/Reportlinker-Adds-Global-Drug-Manufacturing-Industry-Outlook-to-2010-Marketing-and-Sales-Strategies-and-the-Impact-of-Recession-and-Recovery.html ...
... , PHILADELPHIA, October 13 ... specialty biopharmaceutical company, announces,that it has settled all pending ... New Drug Application ("ANDA") and its,attempt to market generic ... treatment of Attention Deficit Hyperactivity,Disorder. , ...
Cached Medicine Technology:Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 2Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 3Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 4Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 5Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 6Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 7Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 8Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 9Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 10Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 11Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 12Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 13Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 14Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 15Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 16Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 17Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 18Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 19Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 20Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R) 2Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R) 3
(Date:3/30/2015)... 30, 2015 Follow us on ... to develop and establish chronic pain rehabilitation centers are ... the market is poised to benefit from the rise ... the increase in chronic health conditions such as Cancer, ... among others. While conventional treatment for pain management is ...
(Date:3/30/2015)... This report studies the global pharmacovigilance and ... of 2014 to 2019. This market is expected ... 2014 to 2019. , Further Inquiry @ ... pharmacovigilance and drug safety software market has been ... functionality, namely, adverse event reporting software, drug safety ...
(Date:3/30/2015)... March 30, 2015 Tel-Aviv – March ... prescription eyewear, announced the closing of $12.5 million in ... of the Viola Group. The funding will further GlassesUSA's ... leading player in the growing global market of online ... in 2009 by CEO Daniel Rothman, COO Eldad Rothman, ...
(Date:3/30/2015)... 30, 2015 On March 19th, 2015, ... home of the Detroit Lions, LiveToBeSober.org hosted the “Fighting ... pastors, ministers and bishops as well as other civic ... audience at the luncheon, including retired Detroit Lions wide ... Wickstrom and two survivors of their own personal battles ...
(Date:3/30/2015)... New York, New York (PRWEB) March 30, 2015 ... of its Top 10 Exotic Water Awards, with the top ... other winners are listed on the company’s website, along with ... Water’s website, exotic water, glacial water, spring water, mineral water ... Fiji water is one of the top exotic water ...
Breaking Medicine News(10 mins):Health News:Technological Developments, Better Patient Awareness & Affordability Drive the Pain Management Devices Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Technological Developments, Better Patient Awareness & Affordability Drive the Pain Management Devices Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4Health News:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 2Health News:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 3Health News:LiveToBeSober.org Releases Highlight Reel of Substance Abuse Conference Keynote Speakers 2Health News:Best Exotic Water Brands Acclaimed by 10 Best Water 2
... study conducted by India and Canada which was carried out by ... decrease in the HIV prevalence. The data revealed that women ... of Tamil Nadu, Maharashtra, Karnataka and Andhra Pradesh had fallen from ... mainly seen in the four south Indian states. , ...
... Heart Journal has said that prayers do not seem to ... recently underwent cardiac bypass surgery. // On the contrary, prayers ... that their condition was far worse than thought. ... and the Baptist Memorial Health Care Corp, tracked the progress ...
... yet to receive AIDS medications from government-funded programs, which are ... to buy costly treatments, //according to an annual survey in ... states were also forced to cut down on the medications ... due to a shortage of funds. "The need for HIV-related ...
... babies who were given an aid to help them breathe ... The way was CNEP therapy - continuous negative-extrathoracic pressure. // ... researchers to the original trial in the early 1990s. ... Southall. ,The Nottingham researchers followed up 133 of ...
... Cephalon has been accorded a further six months of ... disorder treatment medication//, Provigil. ,Cephlaon had ... that entailed the provision of clinical studies data after ... ,Cephalon has settled the ‘provogil’patent infringement litigation with ...
... Australia’s crippled mental health services and community-based care centres. ... would triple for Australia's mental health services and hundreds ... the Government accepts the demands of a parliamentary committee. ... patients from institutions into the community. ...
Cached Medicine News:
... Korchek Technologies CareChek Rx ... barcode technology, Windows CE ... integrated scanners (to perform ... the bedside) and an ...
... Safety Infusion System is designed to ensure ... and the right dose. Available in four ... Safety Infusion System allows hospitals to choose ... their needs. DoseGuard™ dose limit technology and ...
... has an installed base of field-proven ... world. Hospital departments using Intermec media ... Supply, Admissions, Nursing Stations, Pharmacy, Medical ... labeling materials includes many products that ...
... Positive Patient Identification™ (PPI) system is an automated solution that identifies the patient, tying all critical information to ... ... ... ...
Medicine Products: